Drug intelligence / Profile preview

RA7 + RACM7

Development stage: Preclinical
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RA7 + RACM7 is a combination therapy being investigated for the treatment of cancer. RA7 is a monoclonal antibody targeting CD3, while RACM7 is a monoclonal antibody targeting CD28. This combination is designed to enhance T-cell activation and anti-tumor immune responses through dual co-stimulation of T cells.

Targets

CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on RA7 + RACM7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA7 + RACM7.

Explore the full profile